BioCentury | Jun 23, 2016
Distillery Therapeutics

Therapeutics: Integrin avβ3 (CD51/CD61)

...to treat head and neck cancer and lung cancer and preclinical testing to treat melanoma. Tactic Pharma LLC...
BioCentury | Apr 10, 2014
Cover Story

Pre-EMP-tive strike against GBM

...cells Phase II for mesothelioma and NSCLC; Phase I for ovarian cancer and solid tumors Tactic Pharma LLC...
BioCentury | Jul 16, 2012
Company News

Tactic Pharma, Wilson Therapeutics deal

...with ATN-161 within about six months and Phase I development of ATN-658 within 6-9 months. Tactic Pharma LLC...
Items per page:
1 - 3 of 3
BioCentury | Jun 23, 2016
Distillery Therapeutics

Therapeutics: Integrin avβ3 (CD51/CD61)

...to treat head and neck cancer and lung cancer and preclinical testing to treat melanoma. Tactic Pharma LLC...
BioCentury | Apr 10, 2014
Cover Story

Pre-EMP-tive strike against GBM

...cells Phase II for mesothelioma and NSCLC; Phase I for ovarian cancer and solid tumors Tactic Pharma LLC...
BioCentury | Jul 16, 2012
Company News

Tactic Pharma, Wilson Therapeutics deal

...with ATN-161 within about six months and Phase I development of ATN-658 within 6-9 months. Tactic Pharma LLC...
Items per page:
1 - 3 of 3